Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with…
Med Lett Drugs Ther. 2024 Sep 30; 66(1712):153-60 doi:10.58347/tml.2024.1712a
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is…
Med Lett Drugs Ther. 2023 Jan 23; 65(1668):10-2 doi:10.58347/tml.2023.1668b
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast ( Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to be approved by the FDA for this indication; crisaborole (Eucrisa) , another topical PDE4 inhibitor, is approved for treatment of atopic dermatitis. Oral roflumilast (Daliresp) is approved for treatment of chronic obstructive pulmonary disease.
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be…
Med Lett Drugs Ther. 2022 Aug 8; 64(1656):122-4
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.
Med Lett Drugs Ther. 2019 Jun 17; 61(1574):89-96
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids.…
Med Lett Drugs Ther. 2015 Jun 8; 57(1470):81-4
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids. Phototherapy and systemic therapy, including biologic agents, are recommended for patients with moderate to severe disease.
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis.…
Med Lett Drugs Ther. 2010 Jan 25; 52(1330):7-8
The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.
The FDA has approved calcitriol ointment ( Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered…
Med Lett Drugs Ther. 2009 Sep 7; 51(1320):70-1
The FDA has approved calcitriol ointment ( Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more potent than creams or solutions.